Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease

• DOI: 10.1001/archneur.56.6.673
• Publication Date: 2003-03-18T19:38:01Z
• Authors: Niels Andreasen; Camilla Hesse; Pia Davidsson; Lennart Minthon; Anders Wallin; Bengt Winblad; Hugo Vanderstichele; Eugeen Vanmechelen; Kaj Blennow
• Keywords: Amyloid (mycology); Apolipoprotein E

<h3>Objectives</h3> To study the diagnostic potential of 42 amino acid form β-amyloid (β-amyloid_(1-42)) in cerebrospinal fluid (CSF) as a biochemical marker for Alzheimer disease (AD), intra-individual biological variation CSF-β-amyloid_(1-42)level patients with AD, and possible effects differential binding between apolipoprotein E isoforms on CSF-β-amyloid_(1-42)levels. <h3>Design</h3> A 20-month prospective follow-up study. <h3>Setting</h3> Community population-based sample consecutive AD referred to Piteå River Valley Hospital, Piteå, Sweden. <h3>Patients</h3> Fifty-three (mean±SD age, 71.4±7.4 years) diagnosed according National Institute Neurological Communicative Disorders Stroke Alzheimer's Disease Related Association criteria 21 healthy, age-matched 68.8±8.0 control subjects. <h3>Main Outcome Measures</h3> Cerebrospinal β-amyloid_(1-42)level—analyzed using enzyme-linked immunosorbent assay—and severity dementia—analyzed Mini–Mental State Examination. <h3>Results</h3> Mean±SD levels CSF-β-amyloid_(1-42)were decreased (<i>P</i>&lt;.001) (709±304 pg/mL) compared controls (1678±436 pg/mL). Most (49 [92%] 53 patients) had reduced (&lt;1130 highly significant correlation (<i>r</i>=0.90;<i>P</i>&lt;.001) baseline 1-year CSF-β-amyloid_(1-42)levels was found. There were no correlations duration (<i>r</i>=−0.16) or (<i>r</i>=−0.02) dementia. Low also found mild dementia (Mini–Mental Examination score, &gt;25). <h3>Conclusions</h3> The sensitivity is high. low. are earlier stages AD. These findings suggest that CSF-β-amyloid_(1-42)analyses may be value clinical diagnosis especially early course disease, when drug therapy have greatest being effective but particularly difficult.